Airduo Digihaler is owned by Teva Pharm.
Airduo Digihaler contains Fluticasone Propionate; Salmeterol Xinafoate.
Airduo Digihaler has a total of 53 drug patents out of which 0 drug patents have expired.
Airduo Digihaler was authorised for market use on 27 January, 2017.
Airduo Digihaler is available in powder;inhalation dosage forms.
Airduo Digihaler can be used as treatment of asthma.
The generics of Airduo Digihaler are possible to be released after 22 August, 2041.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7540282 | TEVA PHARM | Reservoir pressure system for medicament inhaler |
May, 2023
(2 months from now) | |
US7540282
(Pediatric) | TEVA PHARM | Reservoir pressure system for medicament inhaler |
Nov, 2023
(8 months from now) | |
US9616024 | TEVA PHARM | Process for preparing a medicament |
Sep, 2024
(1 year, 6 months from now) | |
US9987229 | TEVA PHARM | Process for preparing a medicament |
Sep, 2024
(1 year, 6 months from now) | |
US9616024
(Pediatric) | TEVA PHARM | Process for preparing a medicament |
Mar, 2025
(2 years from now) | |
US9987229
(Pediatric) | TEVA PHARM | Process for preparing a medicament |
Mar, 2025
(2 years from now) | |
US10765820 | TEVA PHARM | Dry powder inhalation apparatus |
May, 2025
(2 years from now) | |
US9463288 | TEVA PHARM | Dry powder inhalation apparatus |
May, 2025
(2 years from now) | |
US10765820
(Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Nov, 2025
(2 years from now) | |
US9463288
(Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Nov, 2025
(2 years from now) | |
US8651103 | TEVA PHARM | Dry powder inhalation apparatus |
Mar, 2028
(5 years from now) | |
US8651103
(Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Sep, 2028
(5 years from now) | |
US10195375 | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Feb, 2031
(8 years from now) | |
US9731087 | TEVA PHARM | Dose counter for inhaler having a bore and shaft arrangement |
May, 2031
(8 years from now) | |
US10022510 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(8 years from now) | |
US10124131 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(8 years from now) | |
US9216260 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jun, 2031
(8 years from now) | |
US10195375
(Pediatric) | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Aug, 2031
(8 years from now) | |
US9731087
(Pediatric) | TEVA PHARM | Dose counter for inhaler having a bore and shaft arrangement |
Nov, 2031
(8 years from now) | |
US10124131
(Pediatric) | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Nov, 2031
(8 years from now) | |
US10022510
(Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Nov, 2031
(8 years from now) | |
US9216260
(Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Dec, 2031
(8 years from now) | |
US10561808 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(8 years from now) | |
US8978966 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jan, 2032
(8 years from now) | |
US8714149 | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Feb, 2032
(9 years from now) | |
US10561808
(Pediatric) | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jul, 2032
(9 years from now) | |
US8978966
(Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jul, 2032
(9 years from now) | |
US8714149
(Pediatric) | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Aug, 2032
(9 years from now) | |
US9066957 | TEVA PHARM | Dry powder inhaler |
Oct, 2034
(11 years from now) | |
US9415008 | TEVA PHARM | Dry powder inhaler |
Oct, 2034
(11 years from now) | |
US9066957
(Pediatric) | TEVA PHARM | Dry powder inhaler |
Apr, 2035
(12 years from now) | |
US9415008
(Pediatric) | TEVA PHARM | Dry powder inhaler |
Apr, 2035
(12 years from now) | |
US9782551 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(12 years from now) | |
US9782550 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(12 years from now) | |
US10918816 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Dec, 2035
(12 years from now) | |
US9782550
(Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2036
(13 years from now) | |
US9782551
(Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2036
(13 years from now) | |
US10918816
(Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Jun, 2036
(13 years from now) | |
US10569034 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2036
(13 years from now) | |
US10569034
(Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2037
(14 years from now) | |
US11351317 | TEVA PHARM | Drug delivery device with electronics |
Feb, 2038
(15 years from now) | |
US11351317
(Pediatric) | TEVA PHARM | Drug delivery device with electronics |
Aug, 2038
(15 years from now) | |
US11357935 | TEVA PHARM | Drug delivery device with electronics |
Sep, 2038
(15 years from now) | |
US11000653 | TEVA PHARM | Inhaler |
Dec, 2038
(15 years from now) | |
US11000653
(Pediatric) | TEVA PHARM | Inhaler |
Jun, 2039
(16 years from now) | |
US11344685 | TEVA PHARM | Drug delivery device with electronics |
Sep, 2039
(16 years from now) | |
US11344685
(Pediatric) | TEVA PHARM | Drug delivery device with electronics |
Mar, 2040
(17 years from now) | |
US11439777 | TEVA PHARM | Drug delivery device with electronics |
May, 2040
(17 years from now) | |
US11464923 | TEVA PHARM | Inhaler system |
Jun, 2040
(17 years from now) | |
US11173259 | TEVA PHARM | Drug delivery device with electronics and power management |
Jul, 2040
(17 years from now) | |
US11173259
(Pediatric) | TEVA PHARM | Drug delivery device with electronics and power management |
Jan, 2041
(17 years from now) | |
US11266796 | TEVA PHARM | Inhalation device with integrated electronics |
Feb, 2041
(18 years from now) | |
US11266796
(Pediatric) | TEVA PHARM | Inhalation device with integrated electronics |
Aug, 2041
(18 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Jul 9, 2024 |
Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: Treatment of asthma
Dosage: POWDER;INHALATION
99
United States
47
European Union
37
Japan
30
Spain
28
Israel
28
China
26
Korea, Republic of
24
Australia
22
Hong Kong
22
EA
21
Canada
21
Denmark
16
Poland
14
South Africa
11
Hungary
11
Portugal
9
Cyprus
9
Taiwan, Province of China
8
Peru
7
Mexico
7
Slovenia
7
United Kingdom
7
Argentina
6
Austria
5
Brazil
5
Uruguay
5
Germany
5
New Zealand
3
RS
3
Chile
3
Croatia
3
San Marino
1
Morocco
1
Ukraine
1
IB
1
Colombia
1
Turkey
1
Philippines
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic